A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
NCT02399137
Completed
The purpose of this study is to determine whether the combination of MM-141 plus nab-paclitaxel and gemcitabine is more effective than nab-paclitaxel and gemcitabine alone based on Progression Free Survival (PFS) in front-line metastatic pancreatic cancer patients with high serum levels of free IGF-1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2018
Locations: Banner MD Anderson Cancer Ctr., Gilbert, Arizona +65 locations
Conditions: Pancreatic Cancer
Register for Updates
Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
NCT00404235
Completed
RATIONALE: Drugs used in chemotherapy, such as carboplatin and ABI-007, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects and how well giving carboplatin together with ABI-007 works in treating patients with stage IV melanoma that cannot be removed by surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2018
Locations: Mayo Clinic Scottsdale, Scottsdale, Arizona +155 locations
Conditions: Melanoma (Skin)
Register for Updates
Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics
NCT02297230
Terminated
Paclitaxel 30 mg/m2 twice/week Trastuzumab 4mg/kg, loading dose, then 2 mg/kg weekly and Concurrent RT (to start within one week from first dose of Paclitaxel/Trastuzumab) to breast, supraclavicular, axillary fields, 45 Gy @ 1.8 Gy/fraction, + 14 Gy @ 2 Gy/fraction to the primary tumor. At the end of chemo-radiation, Trastuzumab will be continued weekly until surgery and as per standard of care after surgery for up to 1 year total. \*\*Surgery: Patients will undergo lumpectomy and axillary node... Read More
Gender:
FEMALE
Ages:
Between 18 years and 90 years
Trial Updated:
09/13/2018
Locations: Weill Medical College of Cornell University, New York, New York
Conditions: Breast Cancer
Register for Updates
Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma
NCT02075021
Terminated
The investigators will perform a phase I/II trial of Revlimid daily for 21 days and Abraxane weekly for 3 weeks. Accrual will be on standard cohorts of 3 patients. Once the maximum toxicity dose (MTD) is reached, the level below will be expanded to 25 patients for a pilot phase II trial. All treatments will be performed until progression. Assessments will be made at least at the 2, 4 and 6 month timepoints and monthly thereafter until progression. The purpose of this research study is to determ... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/13/2018
Locations: NYU School of Medicine, New York, New York
Conditions: Relapsed or Refractory Multiple Myeloma
Register for Updates
Excellence in Peripheral Arterial Disease Treatment of Superficial Femoral Artery Disease With Drug-eluting Stents
NCT03671655
Terminated
The superficial femoral artery (SFA) is frequently involved in atherosclerosis and is the most common target of lower extremity endovascular procedures performed in patients with claudication. Endovascular treatment of SFA is challenging, given its exceptional predisposition to atherosclerosis and its exposure to extreme mechanical forces of extension, compression, torsion and flexion. The SFA is located in a fibro-muscular canal, follows a tortuous course and is considered a 'hostile' location... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
09/11/2018
Locations: North Texas Veterans Affairs Health Care System, Dallas, Texas +1 locations
Conditions: Peripheral Vascular Diseases, Chronic Total Occlusion of Artery of the Extremities
Register for Updates
Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer
NCT01493310
Completed
This trial will find the best dose of mifepristone when given together with nab-paclitaxel (Abraxane) based on the side effects of the two drugs in patients with advanced breast cancer. Patients will be randomized to receive nab-paclitaxel with or without mifepristone during the first treatment cycle. After the first cycle, all patients will receive nab-paclitaxel with mifepristone until their disease worsens or they experience an unacceptable side effect. This study will test up to 4 doses of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/10/2018
Locations: University of Chicago, Chicago, Illinois +1 locations
Conditions: Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Register for Updates
Paclitaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors
NCT00004863
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of paclitaxel and GEM 231 in treating patients who have recurrent or refractory solid tumors.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
09/06/2018
Locations: Albert Einstein Comprehensive Cancer Center, Bronx, New York
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma
NCT02181634
Completed
Patients with advanced or metastatic cholangiocarcinoma (CCA) who are not eligible for curative surgery, transplantation, or ablative therapies will receive nab-paclitaxel and gemcitabine chemotherapy. The purpose of this study is to evaluate the effectiveness and safety of the combination of nab-paclitaxel and gemcitabine. The effectiveness will be determined by improvement in the length of time during and after treatment, that the CCA does not get worse.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/05/2018
Locations: Colorado Cancer Research Program, Denver, Colorado +24 locations
Conditions: Cholangiocarcinoma
Register for Updates
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
NCT01621243
Terminated
People with primary metastatic pancreatic cancer will be treated with nab-paclitaxel and gemcitabine in combination with an investigational agent called necuparanib (M402). It is made from heparin, which is a well known blood thinner. Blood thinners have been shown in prior animal and human studies to have anti-cancer effects. Necuparanib has been re-engineered from heparin to have much lower blood thinning activity while keeping the anti-tumor activity. The investigators are testing whether nec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/28/2018
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +36 locations
Conditions: Metastatic Pancreatic Cancer
Register for Updates
Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors
NCT00467051
Completed
This phase II trial is studying how well giving combination chemotherapy works in treating young patients with recurrent or resistant malignant germ cell tumors. Drugs used in chemotherapy, such as paclitaxel, ifosfamide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
08/27/2018
Locations: The University of Arizona Medical Center-University Campus, Tucson, Arizona +94 locations
Conditions: Childhood Extracranial Germ Cell Tumor, Childhood Extragonadal Malignant Germ Cell Tumor, Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor, Ovarian Choriocarcinoma, Ovarian Embryonal Carcinoma, Ovarian Yolk Sac Tumor, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Ovarian Germ Cell Tumor, Testicular Choriocarcinoma, Testicular Embryonal Carcinoma, Testicular Mixed Choriocarcinoma and Embryonal Carcinoma, Testicular Mixed Choriocarcinoma and Yolk Sac Tumor, Testicular Mixed Embryonal Carcinoma and Yolk Sac Tumor, Testicular Yolk Sac Tumor
Register for Updates
Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer
NCT00112489
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving paclitaxel together with carboplatin works in treating patients with persistent or recurrent stage III or stage IV uterine cancer.
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
08/27/2018
Locations: Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama +109 locations
Conditions: Sarcoma
Register for Updates
Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly
NCT02151149
Completed
Study comparing two regimens of nab-paclitaxel and carboplatin combination in elderly subjects (≥ 70 years old) with advanced NSCLC
Gender:
ALL
Ages:
70 years and above
Trial Updated:
08/20/2018
Locations: Arizona Clinical Research Center, Tucson, Arizona +54 locations
Conditions: Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma, Carcinoma, Large Cell, Lung Neoplasm
Register for Updates